All eligible to vote Principal Investigators (525) from EBMT full membership centres were invited to vote online for the nominated, endorsed and approved Working Party Chair candidates for 2022, in addition to approving the activity reports (President, Secretary and Treasurer) and the bylaw amendment approval of articles 14, 16 and 18.
Voting took place online from Wednesday 9th March, 10h00 CET until Monday 21st March 2022, 20h00 CET.
196 ballots submitted of 525 eligible voters = 37% participation.
Please see the results of this online elections below:
EBMT Working Party Chairs
EBMT Acute Leukaemia Working Party Chair - Fabio Ciceri
|Yes - I approve the candidate||187 votes (99.5%)|
|No - I reject the candidate||1 vote (0.5%)|
Yes - I approve the candidate wins with 99.5% of the vote
188 votes tallied and 8 abstentions
"I am honoured to have been elected by my EBMT colleagues for the position of Chairperson of the ALWP.
A new era of treatment for acute leukemias has begun. For all our community of “transplanters”, the challenge is now, and in the future, to integrate transplant options into the modified landscape of leukemia treatments, contributing to the design of appropriate algorithms in specific categories. Moreover, many new cell & gene Advanced Therapy Medicinal Products (ATMPs) are emerging as alternative cancer immunotherapy options to allogeneic transplantation in leukemia patients. Our community is facing the challenge of re-shaping the position of stem cell transplantation, offering the best option of definite cure without unjustified omissions.
A continuous crosstalk with all players in this evolving scenario is crucial for the future of our field and for our patients. I am convinced that the resources of the ALWP and the EBMT overall, will be highly relevant to this evolution."
EBMT Chronic Malignancies Working Party Chair - Donal McLornan
|Yes - I approve the candidate||171 votes (97.7%)|
|No - I reject the candidate||4 votes (2.3%)|
Yes - I approve the candidate wins with 97.7% of the vote
175 votes tallied and 21 abstentions
"I am honoured to have been elected by my EBMT colleagues for the position of Chair of the Chronic Malignancies Working Party (CMWP). Currently, my combined clinical and academic practice centres predominantly on allogeneic HCT, cellular therapies and myeloid disorders (in particular MPN) at University College Hospital London. I have been involved with the EBMT CMWP for many years and have been the chair of the Myeloproliferative Neoplasm (MPN) sub-committee for the last four. I am looking forward to driving forward, alongside colleagues, academic output from our working party across the breadth of disease areas, innovative studies, enhancing further our multimodality educational events and increased CMWP collaboration with other scientific groups such as EHA and the CIBMTR for mutually beneficial data sharing and utilisation. We have expanded our CMWP board membership to meet the requirements of an everchanging landscape and we look forward to sharing our work!"
EBMT Cellular Therapy & Immunobiology Working Party Chair
|Annalisa Ruggeri||140 votes (74.1%)|
|Jürgen Kuball||49 votes (25.9%)|
Annalisa Ruggeri wins with 74.1% of the vote.
189 votes tallied and 7 abstentions
"It is a great honour to have been elected as the new Chair of the CTIWP. I am haematologist at the Hematology and BMT Unit at San Raffaele Hospital in Milan, Italy and I have been working as the CTIWP Secretary for the last 4 years.
My main efforts as the CTIWP chairperson will be towards:
- Promoting the scientific activity of the CTIWP by involving younger investigators
- Improving data collection and data quality of the EBMT registry by continuing trainings and foster communication with transplant centers and data managers and study coordinators
- Strengthening the collaborations with other EBMT working parties and with national and international registries
- Continuing to promote educational events on behalf of EBMT, to deliver high level of science
- Contributing to the involvement of patients advocates and patients representatives to better understand the expected benefits of innovative therapies
- Facilitating the implementation of new tools for data collection and analysis, including the use of new statistical methods
- Establish regular surveys on the new available therapies to ensure their safety and long-term efficiency
Improve communication and collaboration with pharmaceutical companies and regulatory agencies, with the aim of facilitating the development of new therapies."
EBMT Activity Reports and Bylaw Amendment
In addition to voting online for the nominated candidates, PIs were also asked to approve the President's, Secretary's and the Treasurer's reports and the Bylaw Amendment Approval of Article 14, 16 and 18, in advance of the annual General Assembly Meeting 2022.
EBMT President's Activity Report 2018-2021
|Yes - I approve the President's Activity Report 2018-2021||184 votes (98.4%)|
|No - I reject the President's Activity Report 2018-2021||3 votes (1.6%)|
Yes - I approve the President's Activity Report 2018-2021 wins with 98.4% of the vote
187 votes tallied and 9 abstentions
EBMT Treasurer's Annual Report for 2021
|Yes - I approve the Treasurer's Annual Report for 2021||184 votes (100.0%)|
|No - I reject the Treasurer's Annual Report for 2021||0 votes (0%)|
Yes - I approve the Treasurer's Annual Report for 2021 wins with 100.0% of the vote
184 votes tallied and 12 abstentions
EBMT Secretary's Annual Report for 2021
|Yes - I approve the Secretary's Annual Report for 2021||183 votes (99.5%)|
|No - I reject the Secretary's Annual Report for 2021||1 votes (0.5%)|
Yes - I approve the Secretary's Annual Report for 2021 wins with 99.5% of the vote
184 votes tallied and 12 abstentions
Bylaw Amendment Approval of Article 14, 16 and 18
|Yes - I approve the amendments||178 votes (97.8%)|
|No - I reject the amendments||4 votes (2.2%)|
Yes - I approve the amendments wins with 97.8% of the vote
182 votes tallied and 14 abstentions
Outgoing Board Members
We would like to thank the following outgoing Board Members for their support and commitment to the Scientific Council and Board of Association during their mandates:
Nicolaus Kröger, EBMT President 2017 - 2022
Mohamad Mohty, Acute Leukaemia Working Party Chair 2018 – 2022; Scientific Council Chair 2018 – 2020; Scientific Council Representative with the Education Portfolio 2020 – 2022
Ibrahim Yakoub-Agha, Chronic Malignancies Working Party Chair 2018 – 2022
Christian Chabannon, Cellular Therapy & Immunobiology Working Party Chair 2018 – 2022; Scientific Council Co-Chair 2018 – 2020; Scientific Council Representative with the Registry Portfolio 2020 – 2022
Bregje Verhoeven, Patient Advocacy Committee Chair 2018 – 2022